Description: Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Home Page: www.protaratx.com
345 Park Avenue South
New York,
NY
10010
United States
Phone:
646 844 0337
Officers
| Name | Title |
|---|---|
| Mr. Jesse Shefferman | Co-founder, CEO, President & Director |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior VP & Chief Scientific Operations Officer |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer |
| Ms. Hannah Fry | VP, Principal Accounting Officer & Controller |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5218 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |